Tom Murdoch (pictured left with his wife, Ann) was the first QEII patient to be scanned with Ethos and HyperSight imaging.
CAMPAIGN COMPLETED FOR ETHOS TECHNOLOGY WITH HYPERSIGHT™ FOR CANCER CARE
In January 2024, the QEII made Canadian cancer care history by using Ethos technology, paired with HyperSight imaging, to deliver radiation treatment — the first time in the country this was clinically done. Powered by artificial intelligence, Ethos allows QEII care teams to precisely target tumour sites while protecting surrounding organs from potential damage. For some patients, this could mean fewer treatments and side effects, decreased wait times and better outcomes.
Dr. James Robar, chief of medical physics, Nova Scotia Health (centre) with QEII colleagues in front of Ethos technology.
No two patients or diagnoses are the same, with a patient’s treatment needs and anatomy often changing between treatment sessions. Ethos with HyperSight unlocks the ability to adapt a patient’s unique treatment plan in real time before each session. This holds the potential to target radiation beams with unprecedented accuracy thanks to superior image quality that healthcare teams have never seen before.
Care teams are grateful to the donors who made this treatment option a reality and accelerated world-leading research. This project was supported by many donors including leadership gifts from BMO, the Wadih M. Fares Family Foundation, the MacDonald family, and the Jack and Joan Kiuru Foundation, as well as nearly 13,000 riders and supporters of the 2022 BMO Ride for Cancer.
5657 Spring Garden Road
Park Lane Mall, Suite 3005
Halifax, Nova Scotia
B3J 3R4
Phone: 902 334 1546
Toll Free: 1 888 428 0220
Fax: 902 492 8094
Email: info@qe2foundation.ca
Charitable Business No:
88646 3496 RR0001
©2024 QEII Foundation | Privacy Policy
